Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ahj.2006.04.038 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
WATCHMAN versus LACbes® device for percutaneous left atrial appendage closure: a single-center, propensity-matched study.
BMC Cardiovasc Disord
January 2025
Department of Cardiology, Changhai Hospital, Naval Medical University, No. 168 Changhai Road, Yangpu District, Shanghai, 200433, China.
Background: Different left atrial appendage closure (LAAC) devices have been introduced into the clinical setting. A new dual-seal mechanism LACbes® occluder with isogenous barbs for LAAC has been designed to facilitate easier delivery and improve safety. The purpose of this study is to compare the clinical outcomes of the WATCHMAN with those of the LACbes® device for LAAC.
View Article and Find Full Text PDFOutcomes of Concomitant Atrial Fibrillation Ablation and Left Atrial Appendage Closure: A Retrospective Single-Center Experience.
JACC Adv
December 2024
Section of Clinical Cardiac Electrophysiology, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Background: Catheter ablation is an effective therapy in the management of atrial fibrillation (AF). Left atrial appendage closure (LAAC) is an alternative to anticoagulation for stroke prevention in patients with bleeding risks.
Objectives: The purpose of this study was to assess the safety and efficacy of combining AF ablation and LAAC in a single procedure.
Feasibility of combined therapy: percutaneous left atrial appendage closure and transcatheter edge-to-edge repair.
Cardiovasc Interv Ther
November 2024
The Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.
Patients with atrial fibrillation (AF) often present with concomitant significant mitral regurgitation (MR). Percutaneous left atrial appendage closure (LAAC) is indicated for patients with AF to prevent thromboembolism and reduce the need for long-term anticoagulation. Transcatheter edge-to-edge repair (TEER) is recommended for patients with significant MR.
View Article and Find Full Text PDF5-Year Results From the AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial.
J Am Coll Cardiol
November 2024
University Hospital of Bern, Bern, Switzerland.
Background: The Amulet IDE trial (AMPLATZER Amulet Left Atrial Appendage Occluder [LAAO] Investigational Device Exemption [IDE] Trial) evaluated the safety and effectiveness of the Amulet occluder (Abbott) in patients with nonvalvular atrial fibrillation. The Amulet IDE trial is the largest randomized LAAO trial, comparing the Amulet occluder with the Watchman 2.5 device (Boston Scientific).
View Article and Find Full Text PDFPulmonary Artery Injury Following Endocardial Left Atrial Appendage Occlusion: The Known and Unknown.
JACC Clin Electrophysiol
December 2024
Kansas City Heart Rhythm Institute, Overland Park, Kansas, USA. Electronic address:
Article Synopsis
- Left atrial appendage closure (LAAC) is used as an alternative stroke prevention method for patients who cannot take blood thinners, but pulmonary artery injury (PAI) is a rare and serious complication associated with it.
- A review of previous PAI cases and data from the FDA's MAUDE database identified 36 cases, predominantly involving older patients, and highlighted that PAI often presents soon after the procedure, with a significant percentage requiring surgery.
- The study emphasizes the need for heightened awareness of PAI symptoms post-LAAC, especially concerning rapid fluid accumulation around the heart, even without clear predictive signs from imaging or clinical details.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!